Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.

NCT01779336 is registered in ClinicalTrials.gov with Piramal Enterprises Limited as lead sponsor.

NCT NCT01779336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01779336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.
Lead sponsor
Piramal Enterprises Limited
Phase
Phase 1
Overall status
Suspended
Start date
December 31, 2012
Completion date
December 31, 2014
Enrollment
70 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors